Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.195
+0.075 (1.82%)
Apr 9, 2026, 1:36 PM EDT - Market open
Precigen Employees
Precigen had 160 employees as of December 31, 2025. The number of employees increased by 17 or 11.89% compared to the previous year.
Employees
160
Change (1Y)
17
Growth (1Y)
11.89%
Revenue / Employee
$60,525
Profits / Employee
-$2,685,263
Market Cap
1.48B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 160 | 17 | 11.89% | 160 | 0 |
| Dec 31, 2024 | 143 | -59 | -29.21% | 143 | 0 |
| Dec 31, 2023 | 202 | -7 | -3.35% | 202 | 0 |
| Dec 31, 2022 | 209 | -302 | -59.10% | 209 | 0 |
| Dec 31, 2021 | 511 | 34 | 7.13% | 456 | 55 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immatics | 711 |
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Nanobiotix | 103 |
| Bicara Therapeutics | 103 |
PGEN News
- 2 days ago - Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million - Accesswire
- 10 days ago - Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 - PRNewsWire
- 14 days ago - These Analysts Boost Their Forecasts On Precigen Following Q4 Results - Benzinga
- 14 days ago - Precigen Reports Full Year 2025 Financial Results and Business Updates - PRNewsWire
- 4 weeks ago - Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 - PRNewsWire
- 2 months ago - New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - PRNewsWire
- 3 months ago - Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire